Medical Center Haaglanden

At Medical Center Haaglanden, the Surgery department is actively involved in studies across neoplasms and digestive system diseases, with a strong focus on rectal cancer, colon cancer, and esophagogastric cancer. These trials are mainly designed to improve treatment effectiveness, refine surgical outcomes, and reduce recurrence after surgery.

• Research in locally advanced rectal cancer and recurrent rectal cancer aims to improve disease control after surgery.
• Studies in colon cancer and metastatic colorectal cancer are evaluating ways to strengthen long-term survival and lower relapse risk.
• Trials in esophagogastric cancer and HER2-positive esophageal adenocarcinoma are testing better treatment strategies for resectable and advanced disease.

This research combines operative procedures with modern cancer care to support more precise and effective treatment planning.

The site also contributes to blood cancer research within neoplasms, including Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma, multiple myeloma, and T-cell prolymphocytic leukemia. These trials focus on improving treatment response, reducing toxicity, and finding more personalized approaches for people with advanced or relapsed disease.

• Studies in advanced stage Hodgkin lymphoma and early-stage Hodgkin lymphoma are exploring ways to improve cure rates while limiting side effects.
• Research in follicular lymphoma, marginal zone lymphoma, and multiple myeloma is examining new treatment combinations and treatment-free intervals.
• Precision medicine work in advanced solid tumor and hematologic cancers is assessing targeted therapies matched to tumor features.

These studies reflect a strong interest in tailoring oncology care to disease biology and patient needs.

A substantial part of the research portfolio addresses respiratory tract diseases and neoplasms, especially non-small cell lung cancer in both advanced and metastatic settings. The trials are aimed at improving survival, identifying better treatment sequences, and testing new immunotherapy-based strategies.

• Studies in non-small cell lung cancer are evaluating combinations of immunotherapy and chemotherapy to improve outcomes.
• Research in KRAS G12C-positive advanced lung cancer is looking at more effective targeted treatment options.
• Trials in PD-L1-positive lung cancer are exploring whether newer immune-based approaches can outperform current standards.

This area highlights the center’s role in advancing thoracic oncology and more personalized cancer treatment.

Research at the site includes several studies in breast cancer, particularly triple-negative breast cancer, HER2-positive breast cancer, and HR+/HER2- metastatic breast cancer. The main goal is to improve disease control, guide treatment intensity, and support more effective long-term management.

• Trials in triple-negative breast cancer are testing better ways to reduce recurrence after initial treatment.
• Studies in HER2-positive breast cancer are evaluating treatment de-escalation and improved response-guided care.
• Research in hormone receptor-positive breast cancer is examining optimized endocrine and targeted treatment strategies.

These efforts combine medical oncology and precision treatment approaches to improve outcomes for women with early and advanced disease.

The site has an active portfolio in cardiovascular diseases and nervous system diseases, including atrial fibrillation, myocardial infarction, stroke, ischemic stroke, transient ischemic attack, and peripheral arterial disease. These studies are focused on preventing major events, improving recovery, and testing better long-term risk reduction strategies.

• Research in acute myocardial infarction is evaluating therapies to reduce future cardiovascular risk.
• Studies in stroke and intracerebral haemorrhage are looking at safer ways to prevent recurrent events.
• Trials in atrial fibrillation and peripheral arterial disease are assessing treatment strategies that balance benefit and safety.

This work supports better prevention and management of serious cardiovascular and cerebrovascular complications.

Another important field at Medical Center Haaglanden involves nervous system diseases and surgical procedures, especially glioblastoma, brain metastases, subdural hematoma, subarachnoid hemorrhage, and traumatic brain injury. The studies are designed to improve surgical care, support recovery, and evaluate treatments that may reduce complications.

• Research in glioblastoma and brain metastases is testing ways to improve detection and treatment after surgery.
• Trials in chronic subdural hematoma and subarachnoid hemorrhage are assessing approaches to prevent deterioration and limit the need for surgery.
• Studies in traumatic brain injury are exploring therapies that may improve neurological outcomes.

This research combines neurosurgical expertise with efforts to improve safety and recovery in complex brain conditions.

The site’s clinical trials also cover nutritional and metabolic diseases, hormonal diseases, and male urogenital diseases, including obesity, gestational diabetes mellitus, hyperthyroidism, kidney disease, and prostate cancer. The purpose is often to improve disease control, reduce treatment burden, and support healthier long-term outcomes.

• Studies in gestational diabetes and obesity are examining better ways to manage metabolic risk.
• Research in hyperthyroidism is comparing treatment options to preserve thyroid function.
• Trials in kidney disease and prostate cancer are evaluating approaches that may improve survival and reduce treatment burden.

These projects show a broad interest in internal medicine and oncology questions that affect daily clinical care.

Research in bacterial infections, mycoses, and inflammatory conditions includes sepsis, Staphylococcus aureus bacteremia, lower respiratory tract infection, and pulmonary sarcoidosis. In the emergency setting, the site is also studying symptom relief and supportive care for conditions such as acute renal colic.

• Trials in sepsis and bacteremia are evaluating safer and more effective treatment strategies.
• Studies in respiratory infections and pulmonary sarcoidosis are focused on improving clinical recovery and tolerability.
• Emergency care research in renal colic is testing better pain control and patient comfort.

This area reflects a practical focus on improving outcomes in acute and inflammatory medical conditions.

The remaining studies span musculoskeletal diseases, analytical and therapeutic techniques, and other mixed conditions, including Achilles tendinopathy, urolithiasis, and unruptured intracranial aneurysm. These trials often aim to refine diagnosis, improve symptom management, or support better decision-making in everyday clinical practice.

• Research in Achilles tendinopathy is examining more effective ways to relieve pain and improve function.
• Studies in urolithiasis and renal colic are focused on better acute management and reduced hospital use.
• Work in unruptured intracranial aneurysm is assessing strategies to lower the risk of rupture or growth.

Together, these projects show the breadth of clinical research activity across Medical Center Haaglanden, from targeted treatment studies to supportive and preventive care.